A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
NCT07525375
This study is recruiting at 12 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 4 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Research Site · Bakersfield, CA
- Research Site · Lancaster, CA
- Research Site · Long Beach, CA
Florida · 3
- Research Site · Miami, FL
- Research Site · Pembroke Pines, FL
- Research Site · Saint Cloud, FL
Kentucky · 1
- Research Site · Owensboro, KY
Louisiana · 1
- Research Site · Lafayette, LA
Missouri · 1
- Research Site · Columbia, MO
Oklahoma · 1
- Research Site · Oklahoma City, OK
Texas · 2
- Research Site · Lewisville, TX
- Research Site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.